4.6 Article

Photophysical study on DNA & BSA binding and cytotoxic behaviour of piperidine-Pt(II) complexes: Their kinetics & mechanism and molecular docking

Publisher

ELSEVIER SCIENCE SA
DOI: 10.1016/j.jphotochem.2023.114740

Keywords

Pt(II) complexes; Kinetics; DNA/BSA interaction; Anticancer activity; Cell cycle arrest; DFT and molecular docking

Ask authors/readers for more resources

Carrier ligand 2-(Piperidine-1-yl)ethylamine (PIEAM) was used to synthesize Pt(II) complexes as anticancer drug candidates. The complexes were characterized and their substitution reactions were studied. The binding activity with DNA and BSA, as well as the antineoplastic activity, were evaluated. The structural optimization, PASS prediction, and in silico ADME analysis further supported the experimental findings.
For the development of Pt(II) based anticancer drug candidates, carrier ligand 2-(Piperidine-1-yl)ethylamine (PIEAM) was used as a bidentate chelator to synthesize dichloro complex [Pt(PIEAM)Cl2] C-1 and its diaqua [Pt (PIEAM)(OH2)2](X)2 (C-2). The diaqua complex C-2 was further used to synthesize thiol substituted Pt(II)-sulfur complexes with L-cysteine (LC) and N-acetyl-L-cysteine (NAC). The Pt(II) complexes were characterized by multi spectroscopic methods and thermal analysis. The role of electronic and steric factors of carrier ligand PIEAM on substitution reactions of C-2 with LC and NAC was studied in aqueous medium at pH 4.0 under pseudo first-order kinetics and rate constant, equilibrium constant and thermodynamic parameters were calculated. The DNA binding activity and binding mode were confirmed by gel electrophoresis and viscosity measurement. The binding activity of Pt(II) complexes with DNA and BSA was explored by absorption and fluorometric titration methods. In vitro MTT assay of Pt(II) complexes were tested on different cancer cell lines like; MCF 7, A549, HCT 116 and also on normal human embryonic kidney cell HEK 293. The cell cycle arrest of MCF 7 cell growth and also the oxidative stress level (ROS) after treating with Pt(II) complexes were analysed. The structural optimization for molecular docking of Pt(II) complexes at B3LYP functional level were performed to correlate the experimental findings. The antineoplastic activity and drug likeness behaviour of Pt(II) complexes were further supported by PASS prediction and in silico ADME analysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available